Core Viewpoint - Park Ha Biological Technology Co., Ltd. has successfully completed a follow-on public offering, raising approximately US$2.45 million to support its expansion efforts in China [1][3]. Group 1: Offering Details - The company closed a best-efforts follow-on public offering of 21,875,000 units at an offering price of US$0.112 per unit [1]. - Each unit consists of one Class A ordinary share and one warrant to purchase one Class A ordinary share, with an exercise price of US$0.112 [2]. - The warrants are exercisable starting from the issuance date and will expire one year after the issuance [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for the expansion of directly operated stores in China, with specific allocations depending on market conditions [3]. Group 3: Company Overview - Park Ha Biological Technology Co., Ltd. was established in 2016 and focuses on developing its private skincare label and promoting franchise alliances under the brand "Park Ha" [5]. - As of April 30, 2025, the company operates three directly operated stores and has 39 franchisees in China [5]. - The company offers a "light beauty experience" as a value-added service in its stores, enhancing customer satisfaction [5].

Core Viewpoint - International Tower Hill Mines Ltd. has announced a public offering of 29,280,000 common shares at a price of US$2.22 per share, aiming to raise approximately US$105 million in gross proceeds to fund the Livengood Gold Project [1][2][3]. Group 1: Offering Details - The public offering is priced at US$2.22 per common share, with Paulson & Co. Inc. committing to purchase US$40 million in a concurrent private placement at the same price [1][2]. - The total gross proceeds from both the offering and the concurrent private placement are expected to be around US$105 million before expenses [2]. - The underwriters have an option to purchase an additional 4,392,000 common shares, which could increase total gross proceeds to approximately US$115 million if exercised [5]. Group 2: Use of Proceeds - The net proceeds from the offering and the concurrent private placement will be utilized for exploration and development of the Livengood Gold Project, including various studies and community engagement efforts [3]. Group 3: Underwriters and Closing - BMO Capital Markets is the lead book-running manager for the offering, with several other banks acting as book-running managers [4]. - The offering is expected to close around January 27, 2026, and is not contingent upon the completion of the concurrent private placement [5][7]. Group 4: Company Background - International Tower Hill Mines Ltd. holds a 100% interest in the Livengood Gold Project, located 70 miles north of Fairbanks, Alaska [11].

MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the “Offering”) of 40,000,000 shares of its common stock, including the exercise in full of the underwriters’ option to purchase addit ...

Core Viewpoint - Axogen, Inc. has announced an upsized public offering of 4,000,000 shares of common stock priced at $31.00 per share, aiming to raise approximately $124 million before expenses [1][3]. Group 1: Offering Details - The public offering is set to close on January 23, 2026, pending customary closing conditions [2]. - Wells Fargo Securities and Mizuho are the lead book-running managers, with Canaccord Genuity and Raymond James serving as co-managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for early payoff and termination of a term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [3]. Group 3: Regulatory Information - The offering is made under an automatic shelf registration statement on Form S-3ASR, effective upon filing with the SEC on January 21, 2026 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available for free on their website [4]. Group 4: Company Overview - Axogen focuses on the development and commercialization of technologies for peripheral nerve repair, aiming to establish nerve repair as the standard of care [6]. - The company's product portfolio includes various nerve repair solutions such as Avance® and Axoguard® products [7].

Core Viewpoint - Lavras Gold Corp. has announced a bought deal offering of 2,942,000 common shares at C$3.40 per share, aiming to raise approximately C$10 million for project development and exploration activities [1][2]. Group 1: Offering Details - The offering price is set at C$3.40 per share, with total gross proceeds expected to be around C$10,002,800 [1]. - An over-allotment option allows underwriters to purchase an additional 441,300 shares within 30 days, potentially raising an extra C$1,500,420 if fully exercised [2]. - The offering is expected to close on or before January 29, 2026, subject to regulatory approvals [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for project development, exploration, resource drilling, and general corporate purposes [2]. Group 3: Regulatory and Access Information - The shares will be offered through a prospectus supplement to the base shelf prospectus filed in Canada, excluding Quebec [3]. - Access to the prospectus documents will be available on SEDAR+ within two business days [5].

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million to support its growth and clinical strategy [1][4]. Group 1: Offering Details - The public offering consists of 34,782,609 shares priced at $5.75 each, with expected gross proceeds of around $200 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 5,217,391 shares at the public offering price [2]. - The offering is set to close on January 22, 2026, pending customary closing conditions [1]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, with a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the offering [3]. - The completion of the private placement is contingent on the successful completion of the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the offering and private placement will be used to advance the clinical strategy, including the DurAVR® THV global pivotal trial for severe aortic stenosis [4]. - Additional funds will support the expansion of manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining funds allocated to working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is a global structural heart company focused on developing innovative medical devices to restore heart function [10]. - The lead product, DurAVR® THV, is designed to treat aortic stenosis and is made from Anteris' patented ADAPT® tissue technology, which has been used in over 55,000 patients worldwide [11].

Core Viewpoint - Anteris Technologies Global Corp. is initiating a public offering of $200 million in common stock, with an additional $30 million option for underwriters, alongside a private placement of up to $90 million to Medtronic plc, aimed at supporting growth and clinical strategy execution [1][2][3]. Group 1: Offering Details - The company is offering $200 million of its common stock through a proposed underwritten public offering, with a 30-day option for underwriters to purchase an additional $30 million [1]. - Anteris has agreed to sell up to $90 million of common stock to Medtronic in a private placement, contingent on the completion of the public offering [2]. - The shares in the public offering are being offered under a shelf registration statement filed with the SEC, effective January 8, 2026 [5]. Group 2: Use of Proceeds - The net proceeds from the offering and private placement will be used to support the next stage of growth, including the PARADIGM Trial for the DurAVR Transcatheter Heart Valve and expansion of manufacturing capabilities [3]. - A portion of the proceeds will also fund ongoing research and development for v2vmedtech, inc., with the remainder allocated to working capital and general corporate purposes [3]. Group 3: Company Overview - Anteris Technologies is a global structural heart company focused on developing medical devices to restore heart function, with a significant presence in both Australia and the USA [9]. - The company's lead product, the DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [10].

Core Viewpoint - BriaCell Therapeutics Corp. has successfully closed a public offering of 5,366,726 units, raising approximately US$30 million to support its business objectives and working capital needs [1][2]. Group 1: Offering Details - Each unit in the offering consists of one common share (or one pre-funded warrant) and one warrant, sold at a price of US$5.59 per unit [1]. - The warrants are immediately exercisable at an exercise price of US$6.93 per share and will expire five years from the date of issuance [1]. - The warrants have been approved for listing on the Nasdaq Capital Market under the symbol "BCTXL" and began trading on January 14, 2026 [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital requirements, general corporate purposes, and advancing the company's business objectives [2]. Group 3: Regulatory Information - A registration statement related to the securities was filed with the SEC on December 23, 2025, and became effective on January 13, 2026 [3]. - The offering was conducted in accordance with the exemption set forth in Section 602.1 of the TSX Company Manual [2]. Group 4: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [5].

Core Viewpoint - Hallador Energy Company has announced a public offering of 2,777,778 shares of common stock at a price of $18.00 per share, aiming to raise approximately $50 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering consists of 2,777,778 shares priced at $18.00 each, with total gross proceeds expected to be around $50 million [1]. - Hallador has granted underwriters a 30-day option to purchase an additional 416,666 shares [1]. - The closing of the offering is anticipated to occur on or about January 15, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, which may include funding initial financial commitments for equipment to support a planned additional natural gas generating facility [2]. Group 3: Company Overview - Hallador Energy Company is a vertically-integrated Independent Power Producer (IPP) based in Terre Haute, Indiana, with two core businesses: Hallador Power Company, LLC, which operates the Merom Generating Station, and Sunrise Coal, LLC, which supplies fuel to the station and other companies [6].

Group 1 - BriaCell Therapeutics Corp. announced a public offering of 5.367 million units priced at $5.59 per unit, aiming for gross proceeds of approximately $30 million [1] - Each unit consists of one common share and one warrant, with the warrant exercisable at $6.93 per share and expiring five years from issuance [1] - Following the announcement, the stock price dropped 54.12% to $5.01 [2] Group 2 - The warrants have been approved for listing on the Nasdaq Capital Market under the symbol "BCTXL," expected to begin trading on January 14, 2026 [2] - The offering is anticipated to close on January 15, 2026 [2] - The company plans to use the net proceeds for working capital and general corporate purposes [3] Group 3 - BriaCell recently reported a sustained complete resolution of lung metastasis in a breast cancer patient treated with its Bria-OTS personalized immunotherapy, boosting stock prices to $12.10 [3] - Over 11 months, the treatment response was confirmed without treatment-limiting toxicities, enhancing confidence in the Bria-OTS platform [4] - The stock traded between $3.00 and $98.20 over the past year, closing at $10.92, up 43.12% prior to the offering announcement [4]